Cytochrome aa3 is one of two terminal oxidases expressed in free-living Bradyrhizobium japonicum but not symbiotically in bacteroids. Difference spectra (dithionite reduced minus ferricyanide oxidized) for membranes from cells incubated with progressively lower 02 concentrations showed a concomitant decrease in theA603, the absorption peak characteristic of cytochrome aa3. The level of N,N,N',N'-tetramethyl-p-phenylenediamine oxidase activity, a measure of cytochrome aa3 activity, was also found to depend on the 02 level. Dot blots of total RNA isolated from cells grown at various 02 levels were probed with a fragment of the coxA gene from B. japonicum; a sixfold reduction in transcription from the highest (250 ,M) to the lowest (12.5 ,uM) 02 concentration was observed. Bacteroids had even less coxA message, approximately 19%O that in the 12.5 ,uM 02-incubated cells. Primer extension analysis established the transcription initiation site of the coxA gene at 72 bases upstream of the putative translational start codon. Sequence analysis of the region upstream of the transcription initiation site revealed no homology with previously reported B. japonicum promoters.

No abstract

Dithionite-reduced minus ferricyanide-oxidized difference spectra on membranes from Rhizobium tropici (formerly Rhizobium leguminosarum bv. phaseoli) incubated at progressively lower 02 concentrations showed only a slight concomitant decrease in A603, the eL-peak of cytochrome aa3. In contrast to previous results on Bradyrhizobiumjaponicum, R. tropici showed no significant 02-mediated reduction in the level of either coxA transcription or cytochrome aa3 activity (as measured by ascorbate-N,N,N',N'-tetramethyl-p-phenylenediamine [TMPDJ oxidase) even in the cells incubated at 12.5 ,uM 02. Bean nodule R. tropici bacteroids contained 65% of the fully aerobic free-living levels of the coxA transcript. Primer extension analyses established the transcription initiation site of the R. tropici coxA genes. Sequence analyses of the regions upstream of the transcription initiation site revealed no homology with previously reported Rhizobiaceae family promoters, including the coxA promoter ofB.japonicum. The R. tropici deduced CoxA sequence itself is highly homologous to the B. japonicum and Paracoccus denitrificans CoxA sequences. In both B. japonicum and R. tropici, coxA4 transcript levels were the same for cells grown with copper (0.02 PM) in the medium or in medium completely devoid of copper. However, a posttranscriptional effect of copper deprivation was observed for both bacteria; difference absorption spectra on membranes from cells grown without copper showed that B. japonicum lacked spectroscopically detectable cytochrome aa3, whereas R. tropici retained approximately 50%o of normal cytochrome aa3 levels.

No abstract

<div>Abstract<p><b>Purpose:</b> ONC201 is a small-molecule selective antagonist of the G protein–coupled receptor DRD2 that is the founding member of the imipridone class of compounds. A first-in-human phase I study of ONC201 was conducted to determine its recommended phase II dose (RP2D).</p><p><b>Experimental Design:</b> This open-label study treated 10 patients during dose escalation with histologically confirmed advanced solid tumors. Patients received ONC201 orally once every 3 weeks, defined as one cycle, at doses from 125 to 625 mg using an accelerated titration design. An additional 18 patients were treated at the RP2D in an expansion phase to collect additional safety, pharmacokinetic, and pharmacodynamic information.</p><p><b>Results:</b> No grade >1 drug-related adverse events occurred, and the RP2D was defined as 625 mg. Pharmacokinetic analysis revealed a <i>C</i>_max of 1.5 to 7.5 μg/mL (∼3.9–19.4 μmol/L), mean half-life of 11.3 hours, and mean AUC of 37.7 h·μg/L. Pharmacodynamic assays demonstrated induction of caspase-cleaved keratin 18 and prolactin as serum biomarkers of apoptosis and DRD2 antagonism, respectively. No objective responses by RECIST were achieved; however, radiographic regression of several individual metastatic lesions was observed along with prolonged stable disease (>9 cycles) in prostate and endometrial cancer patients.</p><p><b>Conclusions:</b> ONC201 is a selective DRD2 antagonist that is well tolerated, achieves micromolar plasma concentrations, and is biologically active in advanced cancer patients when orally administered at 625 mg every 3 weeks. <i>Clin Cancer Res; 23(15); 4163–9. ©2017 AACR</i>.</p></div>